Swedish consumer health innovator Sigrid has successfully secured $5 million in a new funding round, elevating its total capital raised to approximately $27 million. This investment, supported by both existing and new international backers, underscores strong confidence in the company's clinically validated metabolic health solutions. The fresh capital is designated to accelerate Sigrid's commercial expansion in the United States and advance the development of its proprietary SiPore® technology platform.
Responding to Rising Demand for Metabolic Health Solutions
As metabolic health emerges as a global priority, there is a growing demand for practical, science-backed solutions that effectively manage blood sugar and weight. Sigrid's flagship dietary supplement, Glucose Stabiliser, is experiencing rapid adoption through direct-to-consumer channels and an expanding U.S. physician network. The product has achieved more than threefold revenue growth over the past twelve months, demonstrating a strong product-market fit and high repeat usage in a competitive category.
Fueling Commercial Growth in the United States
According to Co-Founder and CEO Sana Alajmovic, a fundamental shift is occurring in how people approach their metabolic well-being, with rising expectations for clinically proven options. She stated that Sigrid's non-systemic platform technology is uniquely positioned to meet this demand for sustainable weight management and blood sugar control. This latest investment provides the necessary resources to significantly accelerate the company's commercial footprint and strategic initiatives across the U.S. market.
Progressing Towards European Regulatory Approval
A significant portion of the new capital will also be directed toward achieving key regulatory milestones in Europe. Following the successful submission of its technical file, Sigrid is advancing toward CE-mark approval for a pioneering over-the-counter medical device. This device is designed to support weight reduction and improve metabolic health in adults with excess weight as part of a structured lifestyle management program.
Expanding the SiPore® Platform into New Verticals
Looking beyond metabolic health, Sigrid is strategically expanding its patented SiPore® platform to unlock future growth in several adjacent industries. The company is actively exploring promising applications in oral care, veterinary health, and food technology, leveraging the technology's unique mechanical action. This diversification strategy is central to Sigrid's long-term vision of becoming a multi-faceted medtech leader based on its core innovation.
To realize this broader vision, the company is currently engaged in partnership discussions with leading consumer health, nutrition, and pharmaceutical organizations. These potential collaborations focus on licensing and distribution agreements that would embed SiPore®-powered solutions into established global brands. Such partnerships would enable Sigrid's technology to reach millions of new consumers worldwide through trusted and established channels.
This $5 million capital injection marks a pivotal moment for Sigrid, positioning the company for its next significant phase of growth. The funding will not only scale its U.S. presence and advance European regulatory goals but also drive the diversification of its innovative SiPore® platform. This strategic move signals Sigrid's evolution from a fast-growing consumer health brand into a broader, technology-driven medtech player on the global stage.